Ultragenyx Pharmaceutical (RARE) vs Tyra Biosciences (TYRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Tyra Biosciences (TYRA) has outperformed Ultragenyx Pharmaceutical (RARE) over the past year, gaining 46.5% versus a loss of 50.5%. Over five years, TYRA leads with a +22.2% price change compared with -80.9% for RARE. Ultragenyx Pharmaceutical is the larger company by market cap ($1.52 billion vs $1.38 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RARE | TYRA |
|---|---|---|
| Share price | $15.41 | $20.10 |
| Market cap | $1.52B | $1.38B |
| 1-day change | +0.80% | +0.65% |
| YTD return | -33.52% | -24.04% |
| 1-year return | -50.45% | +46.52% |
| 5-year return | -80.89% | +22.22% |
| Forward P/E | 22.77 | — |
| EPS (TTM) | $-5.82 | $-2.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $673.00M | — |
| Revenue growth (YoY) | +20.18% | — |
| Net income (latest FY) | $-575.00M | — |
| Operating margin | -79.49% | — |
| Net margin | -85.44% | — |
| 52-week high | $39.89 | $40.65 |
| 52-week low | $12.73 | $13.29 |
| Distance from 52-week high | -61.36% | -50.55% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +82.01% | +136.07% |
| Average volume | 3.87M | 859.95K |
| Shares outstanding | 98.59M | 68.76M |
| Employees | 1,371 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TYRA has outperformed RARE by 97.0 percentage points over the past year.
About Ultragenyx Pharmaceutical
RARE stock →Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,371 employees
About Tyra Biosciences
TYRA stock →Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
RARE vs TYRA FAQ
Which is bigger, Ultragenyx Pharmaceutical or Tyra Biosciences?
Ultragenyx Pharmaceutical (RARE) is larger, with a market capitalization of $1.52B compared with $1.38B for Tyra Biosciences (TYRA).
Which stock has performed better over the past year, RARE or TYRA?
TYRA returned +46.52% over the past 12 months, compared with -50.45% for RARE (price return, excluding dividends). Past performance does not predict future results.
Are Ultragenyx Pharmaceutical and Tyra Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.